Drug Nanocrystals for Active Tumor-Targeted Drug Delivery

Drug nanocrystals, which are comprised of active pharmaceutical ingredients and only a small amount of essential stabilizers, have the ability to improve the solubility, dissolution and bioavailability of poorly water-soluble drugs; in turn, drug nanocrystal technology can be utilized to develop nov...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 14; no. 4; p. 797
Main Authors Lu, Linwei, Xu, Qianzhu, Wang, Jun, Wu, Sunyi, Luo, Zimiao, Lu, Weiyue
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 06.04.2022
MDPI
Subjects
active targeting
Bioavailability
cancer
Cancer therapies
Chemotherapy
Crystallization
drug delivery
drug nanocrystals
Drugs
Fourier transforms
Homogenization
Microscopy
Nanocrystals
NMR
Nuclear magnetic resonance
Particle size
Pharmaceuticals
Review
Solvents
Spectrum analysis
Tumors
cancer
drug nanocrystals
drug delivery
active targeting
Online AccessGet full text

Cover

More Information
Summary:Drug nanocrystals, which are comprised of active pharmaceutical ingredients and only a small amount of essential stabilizers, have the ability to improve the solubility, dissolution and bioavailability of poorly water-soluble drugs; in turn, drug nanocrystal technology can be utilized to develop novel formulations of chemotherapeutic drugs. Compared with passive targeting strategy, active tumor-targeted drug delivery, typically enabled by specific targeting ligands or molecules modified onto the surface of nanomedicines, circumvents the weak and heterogeneous enhanced permeability and retention (EPR) effect in human tumors and overcomes the disadvantages of nonspecific drug distribution, high administration dosage and undesired side effects, thereby contributing to improving the efficacy and safety of conventional nanomedicines for chemotherapy. Continuous efforts have been made in the development of active tumor-targeted drug nanocrystals delivery systems in recent years, most of which are encouraging and also enlightening for further investigation and clinical translation.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14040797